Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

7 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
5(45.5%)
N/A
4(36.4%)
Phase 2
2(18.2%)
11Total
Phase 1(5)
N/A(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07379125Phase 1Not Yet Recruiting

Therapeutic RSK1 Targeting in Myelofibrosis

Role: collaborator

NCT05837455Phase 2Recruiting

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Role: collaborator

NCT06945042Not ApplicableRecruiting

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Role: collaborator

NCT05944562Phase 1Active Not Recruiting

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Role: collaborator

NCT03900793Phase 1Recruiting

Losartan + Sunitinib in Treatment of Osteosarcoma

Role: collaborator

NCT06593106Not ApplicableRecruiting

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Role: collaborator

NCT06580106Recruiting

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Role: collaborator

NCT06559709Not ApplicableCompleted

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Role: collaborator

NCT05641961Not ApplicableRecruiting

Mobile App to Help Survivors of Childhood Cancer Navigate Long-Term Follow-Up Care

Role: collaborator

NCT06047977Phase 1Recruiting

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Role: collaborator

NCT02324543Phase 1Completed

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Role: collaborator

NCT01459614Phase 2Completed

Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer

Role: collaborator

NCT02558205Withdrawn

Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry

Role: collaborator

All 13 trials loaded